MVVC 2 - Field trials of a new combination malaria vaccine in West African Adults and Children

MVVC 2 - Field trials of a new combination malaria vaccine in West African Adults and Children

Objectives

The Malaria Vectored Vaccine Consortium (MVVC) 2 builds on the established network of MVVC 1, which aims to develop a malaria vaccine candidate, while building capacity at the African clinical trial sites and driving the development of a strong network of its partners.

This project will aim to determine whether addition of a circumsporozoite protein (CSP) particle in adjuvant will enhance the efficacy of vectored prime-boost vaccines for P. falciparum.

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Partner(s)

Key facts

  • Dates
    Dec 2012 to Nov 2014
    Funding amount
    $1,031,150
    Funding information
    Total funding was $1,431,430, awarded by EDCTP and other donors
    Country
    • Kenya
    • Germany
    • United Kingdom
    • Burkina Faso
    • Gambia
    • Ghana
    • Senegal

MESA tags

  • Methodology
    Product development & clinical research, Training & capacity building
    Theme(s)
    Other